Although the introduction of bortezomib as a therapeutic strategy has improved the overall survival of multiple myeloma (MM) patients, 15-20% of high-risk patients do not respond to bortezomib over time or become resistant to treatment. Therefore, the development of new therapeutic strategies, such as combination therapies, is urgently needed.
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
Di Lernia, Giuseppe;Leone, Patrizia;Solimando, Antonio Giovanni;Saltarella, Ilaria;Ria, Roberto;Silvestris, Nicola;Crudele, Lucilla;Vacca, Angelo;Racanelli, Vito
2020-01-01
Abstract
Although the introduction of bortezomib as a therapeutic strategy has improved the overall survival of multiple myeloma (MM) patients, 15-20% of high-risk patients do not respond to bortezomib over time or become resistant to treatment. Therefore, the development of new therapeutic strategies, such as combination therapies, is urgently needed.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
